The efficacy of valsartan and amlodipine combined in the management of hypertension-related type 2 diabetic mellitus

Abstract

The goal of this study is to determine if individuals with hypertension and type 2 diabetes mellitus (T2DM) benefit
from taking valsartan and amlodipine together. Methods: Between July 2018 and October 2022, 110 patients who
received treatment at North China Electric Power University Hospital in Beijing, China had their medical records
reviewed retrospectively. The experimental group (SG; n = 60) took one tablet of co-formulated valsartan (80 mg)
and amlodipine (5 mg) daily for six months, in contrast to the control group (CG; n = 50) that took oral amlodipine
(5 mg) daily. Insulin and atorvastatin calcium were also prescribed to all patients along with the aforementioned
medications. After six months of therapy, researchers evaluated CG and SG based on therapeutic efficacy and side
effect occurrence. We evaluated blood pressure indices (diastolic blood pressure, systolic blood pressure) with blood
glucose-related indices (glycosylated hemoglobin, fasting blood glucose, and 2 hours postprandial blood glucose).
The results indicated that both groups saw a substantial drop in 2 h PG, FBG, HbA1c, SBP, and DBP after
treatment compared to the pre-treatment values (p < 0.05). However, when comparing SG to CG, the 2 h PG, FBG,
HbA1c, SBP, and DBP in SG were considerably lower (p < 0.05). Comparison between CG and SG revealed a
considerably decreased overall response rate (ORR) (p < 0.05). Compared to CG, the incidence of side effects was
significantly lower in SG (p < 0.05). Conclusion: Treating type 2 diabetes with hypertension simultaneously with
valsartan and amlodipine is an effective and safe way to regulate blood sugar and blood pressure. To determine
the validity of these results, further experiments are needed. Diabetes mellitus type 2, valsartan, amlodipine,
hypertension.